Global Porcine Vaccine Market: Industry Analysis and Forecast (2019-2026): By Technology, Disease Indication, End User and Region.

Global Porcine Vaccine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at a 7.5% CAGR of around during a forecast period. To know about the Research Methodology :- Request Free Sample Report Government initiatives for encouraging animal farming combined with immense demand for pork and bacon are touted to drive the demand for vaccines. A large number of hog farms because of the export of pig end products to Asia and other regions can bolster the market size. The high per capita meat consumption by countries in the EU can facilitate the growth of the porcine vaccines market globally. But high storage cost of these vaccines may hinder the market growth. The scope of the report includes a detailed study of global and regional markets for Global porcine vaccine market with the reasons given for variations in the growth of the industry in certain regions.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The report on the global porcine vaccine market covers segments such as technology, disease indication, and end-user industries. Based on end-user, the hog/pig production farm segment accounted for a leading share of the global porcine vaccines market in 2018 and is expected to gain market share by 2026. Growth of specialized pig production units in major countries worldwide and growing demand for pork meat and byproducts such as gelatin have led to prominent share by the hog production farms segment in the porcine vaccines market globally. North America is expected to witness the fastest growth during the forecast period because of the subsequent rise of pig farming and growing cases of swine diseases. Rise in pig cultivation and contract farming in the U.S is deemed to trigger the market demand by 2026. Expansion of production facilities in the U.S, owing to the rising export of pig products for consumption can positively impact the regional market growth. Europe holds the second-largest position in the porcine vaccination market and is expected to retain its positioning in the upcoming years of the forecast period. The growth of the market is attributed to the increasing number of production units for swine and a high consumption rate of pork meat. The report also gives a key development in the market for porcine vaccines such as in April 2019, MSD Animal Health made an announced about the launch of its new and innovative triple-action sow care vaccine to fight against leptospirosis, porcine parvoviruses, and erysipelas. This one of a kind immunity vaccine against three dangerous diseases is a massive development in the industry. Some commercially existing (non-autogenous) porcine reproductive and respiratory syndrome (PRRS) vaccines are: Current Name Type Virus Strain Origin Manufacturer Amervac-PRRS Attenuated European Hipra Laboratorios Suvaxyn-PRRS2 Inactivated European Fort Dodge Veterinaria SA Ingelvac PRRS ATP Attenuated North American Boehringer Ingelheim PRRomiSe Inactivated North American Intervet The objective of the report is to present comprehensive analysis of Global Porcine Vaccine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Porcine Vaccine Market dynamics, structure by analyzing the market segments, and project the Global Porcine Vaccine Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Porcine Vaccine Market make the report investor’s guide.

Scope of the Global Porcine Vaccine Market: Inquire before buying

Global Porcine Vaccine Market, By Technology

• Inactivated Vaccines • Live Attenuated Vaccines • Toxoid Vaccines • Recombinant Vaccines • Conjugate Vaccines • DNA Vaccines

Global Porcine Vaccine Market, By Disease Indication

• Diarrhea • Swine Influenza • Arthritis • Bordatella Rhinitis • Porcine Reproductive and Respiratory Virus (PRRSV) • Porcine Circovirus Associated Disease (PCVAD) • Others

Global Porcine Vaccine Market, By End User

• Veterinary Hospitals • Hog/Pig Production Farm

Global Porcine Vaccine Market, By Region

• North America • Asia Pacific • Europe • Middle East & Africa • South America

Key players operating in Global Porcine Vaccine Market

• Bayer AG. • Bimeda Animal Health • Boehringer Ingelheim GmbH • Ceva Sante Animale • Eli Lilly • Merck & Co., Inc. • Merial (Sanofi) • Vetoquinol • Zoetis, Inc. • Sanofi S.A. • PBS Animal Health, • Aptimmune • Formosa Biomedical INC • MVP • Shoken Pharmaceutical Co., Ltd • FATRO SpA • MSD Animal Health • HIPRA • Novartis AG
Global Porcine Vaccine Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Porcine Vaccine Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Porcine Vaccine Market Analysis and Forecast 6.1. Global Porcine Vaccine Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Porcine Vaccine Market Analysis and Forecast, By End User 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Porcine Vaccine Market Value Share Analysis, By End User 7.4. Global Porcine Vaccine Market Size (US$ Bn) Forecast, By End User 7.5. Global Porcine Vaccine Market Analysis, By End User 7.6. Global Porcine Vaccine Market Attractiveness Analysis, By End User 8. Global Porcine Vaccine Market Analysis and Forecast, By Technology 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Porcine Vaccine Market Value Share Analysis, By Technology 8.4. Global Porcine Vaccine Market Size (US$ Bn) Forecast, By Technology 8.5. Global Porcine Vaccine Market Analysis, By Technology 8.6. Global Porcine Vaccine Market Attractiveness Analysis, By Technology 9. Global Porcine Vaccine Market Analysis and Forecast, By Disease Indication 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Porcine Vaccine Market Value Share Analysis, By Disease Indication 9.4. Global Porcine Vaccine Market Size (US$ Bn) Forecast, By Disease Indication 9.5. Global Porcine Vaccine Market Analysis, By Disease Indication 9.6. Global Porcine Vaccine Market Attractiveness Analysis, By Disease Indication 10. Global Porcine Vaccine Market Analysis, by Region 10.1. Global Porcine Vaccine Market Value Share Analysis, by Region 10.2. Global Porcine Vaccine Market Size (US$ Bn) Forecast, by Region 10.3. Global Porcine Vaccine Market Attractiveness Analysis, by Region 11. North America Porcine Vaccine Market Analysis 11.1. Key Findings 11.2. North America Porcine Vaccine Market Overview 11.3. North America Porcine Vaccine Market Value Share Analysis, By End User 11.4. North America Porcine Vaccine Market Forecast, By End User 11.4.1. Veterinary Hospitals 11.4.2. Hog/Pig Production Farm 11.5. North America Porcine Vaccine Market Value Share Analysis, By Technology 11.6. North America Porcine Vaccine Market Forecast, By Technology 11.6.1. Inactivated Vaccines 11.6.2. Live Attenuated Vaccines 11.6.3. Toxoid Vaccines 11.6.4. Recombinant Vaccines 11.6.5. Conjugate Vaccines 11.6.6. DNA Vaccines 11.7. North America Porcine Vaccine Market Value Share Analysis, By Disease Indication 11.8. North America Porcine Vaccine Market Forecast, By Disease Indication 11.8.1. Diarrhea 11.8.2. Swine Influenza 11.8.3. Arthritis 11.8.4. Bordatella Rhinitis 11.8.5. Porcine Reproductive and Respiratory Virus (PRRSV) 11.8.6. Porcine Circovirus Associated Disease (PCVAD) 11.8.7. Others. 11.9. North America Porcine Vaccine Market Value Share Analysis, by Country 11.10. North America Porcine Vaccine Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Porcine Vaccine Market Analysis, by Country 11.12. U.S. Porcine Vaccine Market Forecast, By End User 11.12.1. Veterinary Hospitals 11.12.2. Hog/Pig Production Farm 11.13. U.S. Porcine Vaccine Market Forecast, By Technology 11.13.1. Inactivated Vaccines 11.13.2. Live Attenuated Vaccines 11.13.3. Toxoid Vaccines 11.13.4. Recombinant Vaccines 11.13.5. Conjugate Vaccines 11.13.6. DNA Vaccines 11.14. U.S. Porcine Vaccine Market Forecast, By Disease Indication 11.14.1. Diarrhea 11.14.2. Swine Influenza 11.14.3. Arthritis 11.14.4. Bordatella Rhinitis 11.14.5. Porcine Reproductive and Respiratory Virus (PRRSV) 11.14.6. Porcine Circovirus Associated Disease (PCVAD) 11.14.7. Others. 11.15. Canada Porcine Vaccine Market Forecast, By End User 11.15.1. Veterinary Hospitals 11.15.2. Hog/Pig Production Farm 11.16. Steel Canada Porcine Vaccine Market Forecast, By Technology 11.16.1. Inactivated Vaccines 11.16.2. Live Attenuated Vaccines 11.16.3. Toxoid Vaccines 11.16.4. Recombinant Vaccines 11.16.5. Conjugate Vaccines 11.16.6. DNA Vaccines 11.17. Canada Porcine Vaccine Market Forecast, By Disease Indication 11.17.1. Diarrhea 11.17.2. Swine Influenza 11.17.3. Arthritis 11.17.4. Bordatella Rhinitis 11.17.5. Porcine Reproductive and Respiratory Virus (PRRSV) 11.17.6. Porcine Circovirus Associated Disease (PCVAD) 11.17.7. Others. 11.18. North America Porcine Vaccine Market Attractiveness Analysis 11.18.1. By End User 11.18.2. By Technology 11.18.3. By Disease Indication 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Porcine Vaccine Market Analysis 12.1. Key Findings 12.2. Europe Porcine Vaccine Market Overview 12.3. Europe Porcine Vaccine Market Value Share Analysis, By End User 12.4. Europe Porcine Vaccine Market Forecast, By End User 12.4.1. Veterinary Hospitals 12.4.2. Hog/Pig Production Farm 12.5. Europe Porcine Vaccine Market Value Share Analysis, By Technology 12.6. Europe Porcine Vaccine Market Forecast, By Technology 12.6.1. Inactivated Vaccines 12.6.2. Live Attenuated Vaccines 12.6.3. Toxoid Vaccines 12.6.4. Recombinant Vaccines 12.6.5. Conjugate Vaccines 12.6.6. DNA Vaccines 12.7. Europe Porcine Vaccine Market Value Share Analysis, By Disease Indication 12.8. Europe Porcine Vaccine Market Forecast, By Disease Indication 12.8.1. Diarrhea 12.8.2. Swine Influenza 12.8.3. Arthritis 12.8.4. Bordatella Rhinitis 12.8.5. Porcine Reproductive and Respiratory Virus (PRRSV) 12.8.6. Porcine Circovirus Associated Disease (PCVAD) 12.8.7. Others. 12.9. Europe Porcine Vaccine Market Value Share Analysis, by Country 12.10. Europe Porcine Vaccine Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Porcine Vaccine Market Analysis, by Country 12.12. Germany Porcine Vaccine Market Forecast, By End User 12.12.1. Veterinary Hospitals 12.12.2. Hog/Pig Production Farm 12.13. Germany Porcine Vaccine Market Forecast, By Technology 12.13.1. Inactivated Vaccines 12.13.2. Live Attenuated Vaccines 12.13.3. Toxoid Vaccines 12.13.4. Recombinant Vaccines 12.13.5. Conjugate Vaccines 12.13.6. DNA Vaccines 12.14. Germany Porcine Vaccine Market Forecast, By Disease Indication 12.14.1. Diarrhea 12.14.2. Swine Influenza 12.14.3. Arthritis 12.14.4. Bordatella Rhinitis 12.14.5. Porcine Reproductive and Respiratory Virus (PRRSV) 12.14.6. Porcine Circovirus Associated Disease (PCVAD) 12.14.7. Others. 12.15. U.K. Porcine Vaccine Market Forecast, By End User 12.15.1. Veterinary Hospitals 12.15.2. Hog/Pig Production Farm 12.16. U.K. Porcine Vaccine Market Forecast, By Technology 12.16.1. Inactivated Vaccines 12.16.2. Live Attenuated Vaccines 12.16.3. Toxoid Vaccines 12.16.4. Recombinant Vaccines 12.16.5. Conjugate Vaccines 12.16.6. DNA Vaccines 12.17. U.K. Porcine Vaccine Market Forecast, By Disease Indication 12.17.1. Diarrhea 12.17.2. Swine Influenza 12.17.3. Arthritis 12.17.4. Bordatella Rhinitis 12.17.5. Porcine Reproductive and Respiratory Virus (PRRSV) 12.17.6. Porcine Circovirus Associated Disease (PCVAD) 12.17.7. Others. 12.18. France Porcine Vaccine Market Forecast, By End User 12.18.1. Veterinary Hospitals 12.18.2. Hog/Pig Production Farm 12.19. France Porcine Vaccine Market Forecast, By Technology 12.19.1. Inactivated Vaccines 12.19.2. Live Attenuated Vaccines 12.19.3. Toxoid Vaccines 12.19.4. Recombinant Vaccines 12.19.5. Conjugate Vaccines 12.19.6. DNA Vaccines 12.20. France Porcine Vaccine Market Forecast, By Disease Indication 12.20.1. Diarrhea 12.20.2. Swine Influenza 12.20.3. Arthritis 12.20.4. Bordatella Rhinitis 12.20.5. Porcine Reproductive and Respiratory Virus (PRRSV) 12.20.6. Porcine Circovirus Associated Disease (PCVAD) 12.20.7. Others. 12.21. Italy Porcine Vaccine Market Forecast, By End User 12.21.1. Veterinary Hospitals 12.21.2. Hog/Pig Production Farm 12.22. Italy Porcine Vaccine Market Forecast, By Technology 12.22.1. Inactivated Vaccines 12.22.2. Live Attenuated Vaccines 12.22.3. Toxoid Vaccines 12.22.4. Recombinant Vaccines 12.22.5. Conjugate Vaccines 12.22.6. DNA Vaccines 12.23. Italy Porcine Vaccine Market Forecast, By Disease Indication 12.23.1. Diarrhea 12.23.2. Swine Influenza 12.23.3. Arthritis 12.23.4. Bordatella Rhinitis 12.23.5. Porcine Reproductive and Respiratory Virus (PRRSV) 12.23.6. Porcine Circovirus Associated Disease (PCVAD) 12.23.7. Others. 12.24. Spain Porcine Vaccine Market Forecast, By End User 12.24.1. Veterinary Hospitals 12.24.2. Hog/Pig Production Farm 12.25. Spain Porcine Vaccine Market Forecast, By Technology 12.25.1. Inactivated Vaccines 12.25.2. Live Attenuated Vaccines 12.25.3. Toxoid Vaccines 12.25.4. Recombinant Vaccines 12.25.5. Conjugate Vaccines 12.25.6. DNA Vaccines 12.26. Spain Porcine Vaccine Market Forecast, By Disease Indication 12.26.1. Diarrhea 12.26.2. Swine Influenza 12.26.3. Arthritis 12.26.4. Bordatella Rhinitis 12.26.5. Porcine Reproductive and Respiratory Virus (PRRSV) 12.26.6. Porcine Circovirus Associated Disease (PCVAD) 12.26.7. Others. 12.27. Rest of Europe Porcine Vaccine Market Forecast, By End User 12.27.1. Veterinary Hospitals 12.27.2. Hog/Pig Production Farm 12.28. Rest of Europe Porcine Vaccine Market Forecast, By Technology 12.28.1. Inactivated Vaccines 12.28.2. Live Attenuated Vaccines 12.28.3. Toxoid Vaccines 12.28.4. Recombinant Vaccines 12.28.5. Conjugate Vaccines 12.28.6. DNA Vaccines 12.29. Rest Of Europe Porcine Vaccine Market Forecast, By Disease Indication 12.29.1. Diarrhea 12.29.2. Swine Influenza 12.29.3. Arthritis 12.29.4. Bordatella Rhinitis 12.29.5. Porcine Reproductive and Respiratory Virus (PRRSV) 12.29.6. Porcine Circovirus Associated Disease (PCVAD) 12.29.7. Others. 12.30. Europe Porcine Vaccine Market Attractiveness Analysis 12.30.1. By End User 12.30.2. By Technology 12.30.3. By Disease Indication 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Porcine Vaccine Market Analysis 13.1. Key Findings 13.2. Asia Pacific Porcine Vaccine Market Overview 13.3. Asia Pacific Porcine Vaccine Market Value Share Analysis, By End User 13.4. Asia Pacific Porcine Vaccine Market Forecast, By End User 13.4.1. Veterinary Hospitals 13.4.2. Hog/Pig Production Farm 13.5. Asia Pacific Porcine Vaccine Market Value Share Analysis, By Technology 13.6. Asia Pacific Porcine Vaccine Market Forecast, By Technology 13.6.1. Inactivated Vaccines 13.6.2. Live Attenuated Vaccines 13.6.3. Toxoid Vaccines 13.6.4. Recombinant Vaccines 13.6.5. Conjugate Vaccines 13.6.6. DNA Vaccines 13.7. Asia Pacific Porcine Vaccine Market Value Share Analysis, By Disease Indication 13.8. Asia Pacific Porcine Vaccine Market Forecast, By Disease Indication 13.8.1. Diarrhea 13.8.2. Swine Influenza 13.8.3. Arthritis 13.8.4. Bordatella Rhinitis 13.8.5. Porcine Reproductive and Respiratory Virus (PRRSV) 13.8.6. Porcine Circovirus Associated Disease (PCVAD) 13.8.7. Others. 13.9. Asia Pacific Porcine Vaccine Market Value Share Analysis, by Country 13.10. Asia Pacific Porcine Vaccine Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Porcine Vaccine Market Analysis, by Country 13.12. China Porcine Vaccine Market Forecast, By End User 13.12.1. Veterinary Hospitals 13.12.2. Hog/Pig Production Farm 13.13. China Porcine Vaccine Market Forecast, By Technology 13.13.1. Inactivated Vaccines 13.13.2. Live Attenuated Vaccines 13.13.3. Toxoid Vaccines 13.13.4. Recombinant Vaccines 13.13.5. Conjugate Vaccines 13.13.6. DNA Vaccines 13.14. China Porcine Vaccine Market Forecast, By Disease Indication 13.14.1. Diarrhea 13.14.2. Swine Influenza 13.14.3. Arthritis 13.14.4. Bordatella Rhinitis 13.14.5. Porcine Reproductive and Respiratory Virus (PRRSV) 13.14.6. Porcine Circovirus Associated Disease (PCVAD) 13.14.7. Others. 13.15. India Porcine Vaccine Market Forecast, By End User 13.15.1. Veterinary Hospitals 13.15.2. Hog/Pig Production Farm 13.16. India Porcine Vaccine Market Forecast, By Technology 13.16.1. Inactivated Vaccines 13.16.2. Live Attenuated Vaccines 13.16.3. Toxoid Vaccines 13.16.4. Recombinant Vaccines 13.16.5. Conjugate Vaccines 13.16.6. DNA Vaccines 13.17. India Porcine Vaccine Market Forecast, By Disease Indication 13.17.1. Diarrhea 13.17.2. Swine Influenza 13.17.3. Arthritis 13.17.4. Bordatella Rhinitis 13.17.5. Porcine Reproductive and Respiratory Virus (PRRSV) 13.17.6. Porcine Circovirus Associated Disease (PCVAD) 13.17.7. Others. 13.18. Japan Porcine Vaccine Market Forecast, By End User 13.18.1. Veterinary Hospitals 13.18.2. Hog/Pig Production Farm 13.19. Japan Porcine Vaccine Market Forecast, By Technology 13.19.1. Inactivated Vaccines 13.19.2. Live Attenuated Vaccines 13.19.3. Toxoid Vaccines 13.19.4. Recombinant Vaccines 13.19.5. Conjugate Vaccines 13.19.6. DNA Vaccines 13.20. Japan Porcine Vaccine Market Forecast, By Disease Indication 13.20.1. Diarrhea 13.20.2. Swine Influenza 13.20.3. Arthritis 13.20.4. Bordatella Rhinitis 13.20.5. Porcine Reproductive and Respiratory Virus (PRRSV) 13.20.6. Porcine Circovirus Associated Disease (PCVAD) 13.20.7. Others. 13.21. ASEAN Porcine Vaccine Market Forecast, By End User 13.21.1. Veterinary Hospitals 13.21.2. Hog/Pig Production Farm 13.22. ASEAN Porcine Vaccine Market Forecast, By Technology 13.22.1. Inactivated Vaccines 13.22.2. Live Attenuated Vaccines 13.22.3. Toxoid Vaccines 13.22.4. Recombinant Vaccines 13.22.5. Conjugate Vaccines 13.22.6. DNA Vaccines 13.23. ASEAN Porcine Vaccine Market Forecast, By Disease Indication 13.23.1. Diarrhea 13.23.2. Swine Influenza 13.23.3. Arthritis 13.23.4. Bordatella Rhinitis 13.23.5. Porcine Reproductive and Respiratory Virus (PRRSV) 13.23.6. Porcine Circovirus Associated Disease (PCVAD) 13.23.7. Others. 13.24. Rest of Asia Pacific Porcine Vaccine Market Forecast, By End User 13.24.1. Veterinary Hospitals 13.24.2. Hog/Pig Production Farm 13.25. Rest of Asia Pacific Porcine Vaccine Market Forecast, By Technology 13.25.1. Inactivated Vaccines 13.25.2. Live Attenuated Vaccines 13.25.3. Toxoid Vaccines 13.25.4. Recombinant Vaccines 13.25.5. Conjugate Vaccines 13.25.6. DNA Vaccines 13.26. Rest of Asia Pacific Porcine Vaccine Market Forecast, By Disease Indication 13.26.1. Diarrhea 13.26.2. Swine Influenza 13.26.3. Arthritis 13.26.4. Bordatella Rhinitis 13.26.5. Porcine Reproductive and Respiratory Virus (PRRSV) 13.26.6. Porcine Circovirus Associated Disease (PCVAD) 13.26.7. Others. 13.27. Asia Pacific Porcine Vaccine Market Attractiveness Analysis 13.27.1. By End User 13.27.2. By Technology 13.27.3. By Disease Indication 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Porcine Vaccine Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Porcine Vaccine Market Overview 14.3. Middle East & Africa Porcine Vaccine Market Value Share Analysis, By End User 14.4. Middle East & Africa Porcine Vaccine Market Forecast, By End User 14.4.1. Veterinary Hospitals 14.4.2. Hog/Pig Production Farm 14.5. Middle East & Africa Porcine Vaccine Market Value Share Analysis, By Technology 14.6. Middle East & Africa Porcine Vaccine Market Forecast, By Technology 14.6.1. Inactivated Vaccines 14.6.2. Live Attenuated Vaccines 14.6.3. Toxoid Vaccines 14.6.4. Recombinant Vaccines 14.6.5. Conjugate Vaccines 14.6.6. DNA Vaccines 14.7. Middle East & Africa Porcine Vaccine Market Value Share Analysis, By Disease Indication 14.8. Middle East & Africa Porcine Vaccine Market Forecast, By Disease Indication 14.8.1. Diarrhea 14.8.2. Swine Influenza 14.8.3. Arthritis 14.8.4. Bordatella Rhinitis 14.8.5. Porcine Reproductive and Respiratory Virus (PRRSV) 14.8.6. Porcine Circovirus Associated Disease (PCVAD) 14.8.7. Others. 14.9. Middle East & Africa Porcine Vaccine Market Value Share Analysis, by Country 14.10. Middle East & Africa Porcine Vaccine Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Porcine Vaccine Market Analysis, by Country 14.12. GCC Porcine Vaccine Market Forecast, By End User 14.12.1. Veterinary Hospitals 14.12.2. Hog/Pig Production Farm 14.13. GCC Porcine Vaccine Market Forecast, By Technology 14.13.1. Inactivated Vaccines 14.13.2. Live Attenuated Vaccines 14.13.3. Toxoid Vaccines 14.13.4. Recombinant Vaccines 14.13.5. Conjugate Vaccines 14.13.6. DNA Vaccines 14.14. GCC Porcine Vaccine Market Forecast, By Disease Indication 14.14.1. Diarrhea 14.14.2. Swine Influenza 14.14.3. Arthritis 14.14.4. Bordatella Rhinitis 14.14.5. Porcine Reproductive and Respiratory Virus (PRRSV) 14.14.6. Porcine Circovirus Associated Disease (PCVAD) 14.14.7. Others. 14.15. South Africa Porcine Vaccine Market Forecast, By End User 14.15.1. Veterinary Hospitals 14.15.2. Hog/Pig Production Farm 14.16. South Africa Porcine Vaccine Market Forecast, By Technology 14.16.1. Inactivated Vaccines 14.16.2. Live Attenuated Vaccines 14.16.3. Toxoid Vaccines 14.16.4. Recombinant Vaccines 14.16.5. Conjugate Vaccines 14.16.6. DNA Vaccines 14.17. South Africa Porcine Vaccine Market Forecast, By Disease Indication 14.17.1. Diarrhea 14.17.2. Swine Influenza 14.17.3. Arthritis 14.17.4. Bordatella Rhinitis 14.17.5. Porcine Reproductive and Respiratory Virus (PRRSV) 14.17.6. Porcine Circovirus Associated Disease (PCVAD) 14.17.7. Others. 14.18. Rest of Middle East & Africa Porcine Vaccine Market Forecast, By End User 14.18.1. Veterinary Hospitals 14.18.2. Hog/Pig Production Farm 14.19. Rest of Middle East & Africa Porcine Vaccine Market Forecast, By Technology 14.19.1. Inactivated Vaccines 14.19.2. Live Attenuated Vaccines 14.19.3. Toxoid Vaccines 14.19.4. Recombinant Vaccines 14.19.5. Conjugate Vaccines 14.19.6. DNA Vaccines 14.20. Rest of Middle East & Africa Porcine Vaccine Market Forecast, By Disease Indication 14.20.1. Diarrhea 14.20.2. Swine Influenza 14.20.3. Arthritis 14.20.4. Bordatella Rhinitis 14.20.5. Porcine Reproductive and Respiratory Virus (PRRSV) 14.20.6. Porcine Circovirus Associated Disease (PCVAD) 14.20.7. Others. 14.21. Middle East & Africa Porcine Vaccine Market Attractiveness Analysis 14.21.1. By End User 14.21.2. By Technology 14.21.3. By Disease Indication 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Porcine Vaccine Market Analysis 15.1. Key Findings 15.2. South America Porcine Vaccine Market Overview 15.3. South America Porcine Vaccine Market Value Share Analysis, By End User 15.4. South America Porcine Vaccine Market Forecast, By End User 15.4.1. Veterinary Hospitals 15.4.2. Hog/Pig Production Farm 15.5. South America Porcine Vaccine Market Value Share Analysis, By Technology 15.6. South America Porcine Vaccine Market Forecast, By Technology 15.6.1. Inactivated Vaccines 15.6.2. Live Attenuated Vaccines 15.6.3. Toxoid Vaccines 15.6.4. Recombinant Vaccines 15.6.5. Conjugate Vaccines 15.6.6. DNA Vaccines 15.7. South America Porcine Vaccine Market Value Share Analysis, By Disease Indication 15.8. South America Porcine Vaccine Market Forecast, By Disease Indication 15.8.1. Diarrhea 15.8.2. Swine Influenza 15.8.3. Arthritis 15.8.4. Bordatella Rhinitis 15.8.5. Porcine Reproductive and Respiratory Virus (PRRSV) 15.8.6. Porcine Circovirus Associated Disease (PCVAD) 15.8.7. Others. 15.9. South America Porcine Vaccine Market Value Share Analysis, by Country 15.10. South America Porcine Vaccine Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Porcine Vaccine Market Analysis, by Country 15.12. Brazil Porcine Vaccine Market Forecast, By End User 15.12.1. Veterinary Hospitals 15.12.2. Hog/Pig Production Farm 15.13. Brazil Porcine Vaccine Market Forecast, By Technology 15.13.1. Inactivated Vaccines 15.13.2. Live Attenuated Vaccines 15.13.3. Toxoid Vaccines 15.13.4. Recombinant Vaccines 15.13.5. Conjugate Vaccines 15.13.6. DNA Vaccines 15.14. Brazil Porcine Vaccine Market Forecast, By Disease Indication 15.14.1. Diarrhea 15.14.2. Swine Influenza 15.14.3. Arthritis 15.14.4. Bordatella Rhinitis 15.14.5. Porcine Reproductive and Respiratory Virus (PRRSV) 15.14.6. Porcine Circovirus Associated Disease (PCVAD) 15.14.7. Others. 15.15. Mexico Porcine Vaccine Market Forecast, By End User 15.15.1. Veterinary Hospitals 15.15.2. Hog/Pig Production Farm 15.16. Mexico Porcine Vaccine Market Forecast, By Technology 15.16.1. Inactivated Vaccines 15.16.2. Live Attenuated Vaccines 15.16.3. Toxoid Vaccines 15.16.4. Recombinant Vaccines 15.16.5. Conjugate Vaccines 15.16.6. DNA Vaccines 15.17. Mexico Porcine Vaccine Market Forecast, By Disease Indication 15.17.1. Diarrhea 15.17.2. Swine Influenza 15.17.3. Arthritis 15.17.4. Bordatella Rhinitis 15.17.5. Porcine Reproductive and Respiratory Virus (PRRSV) 15.17.6. Porcine Circovirus Associated Disease (PCVAD) 15.17.7. Others. 15.18. Rest of South America Porcine Vaccine Market Forecast, By End User 15.18.1. Veterinary Hospitals 15.18.2. Hog/Pig Production Farm 15.19. Rest of South America Porcine Vaccine Market Forecast, By Technology 15.19.1. Inactivated Vaccines 15.19.2. Live Attenuated Vaccines 15.19.3. Toxoid Vaccines 15.19.4. Recombinant Vaccines 15.19.5. Conjugate Vaccines 15.19.6. DNA Vaccines 15.20. Rest of South America Porcine Vaccine Market Forecast, By Disease Indication 15.20.1. Diarrhea 15.20.2. Swine Influenza 15.20.3. Arthritis 15.20.4. Bordatella Rhinitis 15.20.5. Porcine Reproductive and Respiratory Virus (PRRSV) 15.20.6. Porcine Circovirus Associated Disease (PCVAD) 15.20.7. Others. 15.21. South America Porcine Vaccine Market Attractiveness Analysis 15.21.1. By End User 15.21.2. By Technology 15.21.3. By Disease Indication 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Bayer AG. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Bimeda Animal Health 16.3.3. Boehringer Ingelheim GmbH 16.3.4. Ceva Sante Animale 16.3.5. Eli Lilly 16.3.6. Merck & Co., Inc. 16.3.7. Merial (Sanofi) 16.3.8. Vetoquinol 16.3.9. Zoetis, Inc. 16.3.10. Sanofi S.A. 16.3.11. PBS Animal Health, 16.3.12. Aptimmune 16.3.13. Formosa Biomedical INC 16.3.14. MVP 16.3.15. Shoken Pharmaceutical Co., Ltd 16.3.16. FATRO SpA 16.3.17. MSD Animal Health 16.3.18. HIPRA 16.3.19. Novartis AG 17. Primary Key Insights

About This Report

Report ID 37904
Category Healthcare
Published Date Nov 2019
Updated Date Nov 2020
Contact Us